Camlin Fine Sciences has received board’s approval to raise funds not exceeding Rs 250 crore by way of debt and FCCB/GDR/ADR/ QIP/other securities linked to equity / preference shares / any instrument or securities representing convertible securities.
The meeting of the Board of Directors of the company held on May 24, 2018, have approved the same.
Camlin Fine Sciences is the world's second largest manufacturer and marketer of food grade antioxidants BHA (butylated hydroxyanisole) and TBHQ (Tertiary Butylhydroquinone).